Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer

Journal of Urology

Volumn 163, Issue 6, 2000, Pages 1756-1760

  Leibovich, Bradley C ^a   Cheng, Liang ^a   Weaver, Amy L ^a   Myers, Robert P ^a   Bostwick, David G ^a,b  

^a MAYO CLINIC   (United States)

^b BOSTWICK LABORATORIES   (United States)

Author keywords

Prostate; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Protein p53

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

EID: 0034045170     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67536-2     Document Type: Article

References (39)

1. Pettaway, C. A.: Prognostic markers in clinically localized prostate cancer. Tech Urol, 4: 35, 1998
2. Vesalainen, S., Lipponen, P., Nordling, S. et al: Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biology. Anticancer Res, 15: 569, 1995
3. Bauer, J. J., Connelly, R. R., Seterhenn, I. A. et al: Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol, 159: 929, 1998
4. Bostwick, D. G., Wheeler, T. M., Blute, M. et al: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology, 48: 47, 1996
5. Brawer, M. K.: Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma. Cancer, 78: 345, 1996
6. Stapleton, A. M., Zbell, P., Kattan, M. W. et al: Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer, 82: 168, 1998
7. Bettencourt, M. C., Bauer, J. J., Sesterhenn, I. A. et al: Ki-67 expression is an independent prognostic marker of recurrence in patients with organ confined prostate cancer after radical prostatectomy. J Urol, 156: 1064, 1996
8. Kuczyk, M. A., Serth, J., Bokemeyer, C. et al: The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer, 34: 679, 1998
9. Levine, A. J., Momand, J. and Finlay, C. A.: The p53 tumour suppressor gene. Nature, 351: 453, 1991
10. Levine, A. J.: p53, the cellular gatekeeper for growth and division. Cell, 88: 323, 1997
11. Nigro, J. M., Baker, S. J., Presinger, A. C. et al: Mutations in the p53 gene occur in diverse human tumour types. Nature (London), 342: 705, 1989
12. Hollstein, M., Sidransky, D., Vogelstein, B. et al: p53 mutations in human cancers. Science, 253: 49, 1991
13. Byrne, R. L., Horne, C. H., Robinson, M. C. et al: The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol, 79: 190, 1997
14. Moul, J. W., Bettencourt, M. C., Sesterhenn, I. A. et al.: Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery, 120: 159, 1996
15. Papadopoulos, I., Rudolph, P., Wirth, B. et al: p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Urology, 48: 261, 1996
16. Henke, R.-P., Krüger, E., Ayhan, N. et al: Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol, 152: 1297, 1994
17. Theodorescu, D., Broder, S. R., Boyd, J. C. et al: p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol, 158: 131, 1997
18. Matsushima, H., Kitamura, T., Goto, T. et al: Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol, 158: 2278, 1997
19. Grignon, D. J., Caplan, R., Sarkar, F. H. et al: p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Nat Cancer Inst, 89: 158, 1997
20. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K. et al: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol, 156: 1511, 1996
21. Stricker, H. J., Jay, J. K., Linden, M. D. et al: Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology, 47: 366, 1996
22. Keshgegian, A. A., Johnston, E. and Cnaan, A.: Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol, 110: 443, 1998
23. Salem, C. E., Tomasic, N. A., Elmajian, D. A. et al: p53 protein and gene alterations in pathological stage C prostate carcinoma. J Urol, 158: 510, 1997
24. Uzoaru, I., Rubenstein, M., Mirochnik, Y. et al: An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer. J Surg Oncol, 67: 33, 1998
25. Blackwell, K. L., Bostwick, D. G., Myers, R. P. et al: Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. J Urol, 151: 1565, 1994
26. Morgan, W. R. and Lieber, M. M.: Pelvic lymphadenectomy. In: Current Genitourinary Cancer Surgery. Edited by E. D. Crawford and S. Das. Philadelphia: Lea and Febinger, pp. 162-169, 1990
27. Littrup, P. J., William, C. R., Egglin, T. K. et al: Determination of prostate volume with transrectal US for cancer screening. Part II. Accuracy of in vitro and in vivo techniques. Radiology, 179: 49, 1991
28. Humphrey, P. A. and Vollmer, R. T.: Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens. Hum Pathol, 21: 799, 1990
29. Bostwick, D. G., Graham, S, D., Jr., Napalkov, P. et al: Staging of early prostate cancer: a proposed tumor volume-based prognostic index. Urology, 41: 403, 1993
30. Bostwick, D. G.: Neoplasms of the prostate. In: Urologic Surgical Pathology. Edited by D. G. Bostwick and J. N. Eble. St. Louis: Mosby, pp. 343-422, 1997
31. Nativ, O., Myers, R. P., Farrow, G. M. et al: Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma. J Urol, 144: 303, 1990
32. Perry, A., Stafford, S. L., Scheithauer, B. W. et al: The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer, 82: 2262, 1998
33. Shi, S. R., Key, M. E. and Kalra, K. L.: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem, 39: 741, 1991
34. Harrell, F. E., Jr., Lee, K. L. and Mark, D. B.: Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med, 15: 361, 1996
35. Aprikian, A. G., Sarkis, A. S., Fair, W. R. et al: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol, 151: 1276, 1994
36. Hughes, J. H., Cohen, M. B. and Robinson, R. A.: p53 immuno-reactivity in primary and metastatic prostatic adenocarcinoma. Mod Pathol, 8: 462, 1995
37. Navone, N. M., Troncoso, P., Pisters, L. L. et al: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Nat Cancer Inst, 85: 1657, 1993
38. Humphrey, P. A. and Swanson, P. E.: Immunoreactive p53 protein in high-grade prostatic intraepithelial neoplasia. Pathol Res Pract, 191: 881, 1995
39. Grossfeld, G. D., Olumi, A. F., Connolly, J. A. et al: Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol, 159: 1437, 1998